OBiO Tech(688238)2024-12-20 10:11Group 1: Business Performance - The company's CDMO business revenue for the first three quarters of 2024 reached 107.11 million yuan, a year-on-year increase of 45.94% with new orders exceeding 250 million yuan [2] - The CRO business revenue for the same period was 60.30 million yuan, reflecting a growth of 13.78% year-on-year, serving over 12,000 research laboratory clients [2] - The depreciation and amortization expenses for the first half of 2024 amounted to 44.98 million yuan, primarily due to the gradual commissioning of the Lingang industrial base [2] Group 2: Market Expansion and Policy Support - The company is actively expanding its domestic and international markets, with an increase in new customer orders and progress in clients' new drug pipelines [2] - Various local governments have introduced action plans to promote the development of the gene and cell therapy sectors, providing strong policy support for the industry [3] - In 2024, the State Council approved a comprehensive support plan for innovative drug development, emphasizing the need for policy guarantees across the entire chain [5] Group 3: Strategic Developments - The company established a wholly-owned subsidiary, He Yuan He Mei, focusing on regenerative medicine, marking a significant step in its strategic layout in cell therapy [5] - The Lingang industrial base is expected to alleviate capacity bottlenecks, with new production lines being gradually put into operation [4] - The company aims to enhance its service capabilities and market share by continuously developing new products and exploring overseas markets [2]